Home > Oncology > WCLC 2018 > Mesothelioma > Angiogenic and stromal biomarkers in malignant mesothelioma

Angiogenic and stromal biomarkers in malignant mesothelioma


Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22
Conference
WCLC 2018
Agents that target VEGF receptors (e.g. bevacizumab) and multi-angiokinase inhibitors (e.g. nintedanib) recently demonstrated efficacy in the treatment of malignant mesothelioma in early phase trials [10, 11]. These findings prompted Chia et al. [12] to assess the prognostic implications of VEGF, PDGF, FGF, and the angiogenesis marker, CD31, in malignant mesothelioma. They used formalin-fixed, paraffin-embedded tissue samples from 329 patients to create tissue microarrays. All patients underwent surgical resection or biopsy for malignant mesothelioma between 1988 and 2014. IHC staining via the H-score method was used to analyse VEGF, PDGF, FGFR-1, and CD31 expression. The discriminatory threshold was set for each IHC stain, and samples were classified as low (below median) or high expression (above median). Chalkey’s method [13] was used to evaluate CD31 IHC microvessel density. The final Chalkey score was the mean of three separate counts. Out of...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on